Steven M. Horwitz, MD - Precision Medicine in Hematologic Cancers: Lessons for Diagnostic and Treatment Protocols in CD30- and CD123-Expressing Disease

Go online to PeerView.com/FSD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As precision medicine has taken a varying course in the setting of hematologic cancers, safely integrating effective, novel therapeutics into the management of patients whose cancers express markers such as CD30 and CD123 is more important than ever. In this activity, our experts discuss the diagnostic and treatment implications of these markers in various hematologic disease settings and use workshop-style educational segments with patient cases and clinical scenarios to illustrate the medical benefits of precision medicine for hematologic cancers defined by CD30 and CD123 expressions. Upon completion of this activity, participants should be better able to: Describe the significance of CD30 and CD123 in a range of hematologic cancers, including implications for diagnosis, immunophenotypic/molecular testing, and prognosis, Cite current efficacy and safety evidence on the use of novel therapeutics in CD30-expressing lymphoma, including in patients with newly diagnosed or relapsed disease, Discuss current evidence on the use of CD123-targeting agents in a range of hematologic cancers characterized by CD123 expression, Integrate novel therapeutics into the management of patients with newly diagnosed or relapsed/refractory Hodgkin or T-cell lymphoma, blastic plasmacytoid dendritic cell neoplasm, and chronic myelomonocytic leukemia, Manage safety considerations associated with the use of novel therapeutics in patients with CD30- or CD123-expressing malignancies.